A psychiatrist specialising in sexual dysfunction caused by antidepressants is calling for greater recognition of the problems that can endure after treatment stops. Professor David Healy, writing in the Journal of the Royal Society of Medicine , said problems may begin after only a few doses and leave someone affected for life, or a relatively mild dysfunction can worsen dramatically when the person stops treatment.
Called Post-SSRI Sexual Dysfunction (PSSD), the core features of the condition are genital numbing, loss or muting of orgasm and loss of libido. According to Professor Healy many patients are just as concerned by additional features like emotional numbing or derealisation. Both sexes, all ages and every ethnic group can be affected.
Professor Healy, of Bangor University, said: "10% of people of sexually active years in developed countries are on antidepressants chronically. Nearly 20% of the population, therefore, may not be able to make love the way they want. In some deprived areas, the figure may be much higher. Some likely comfort themselves with the thought that once they stop treatment, they will get back to normal, when in fact they may be even less able to function."
In June 2019, in response to a petition lodged by Professor Healy and colleagues in 2018, the European Medicines Agency asked pharmaceutical companies to warn that sexual dysfunction can endure after antidepressant treatment stops.
Professor Healy said: "There is a great need to recognise these treatment-related enduring sexual dysfunctions and pinpoint how they arise and might be treated." Explore further More information: David Healy, Antidepressants and sexual dysfunction: a history, Journal of the Royal Society of Medicine (2020). DOI: 10.1177/0141076819899299 Journal information: Provided by SAGE Publications Citation : Doctors urged to recognize post-antidepressant sexual dysfunction (2020, January 24) retrieved 24 January 2020 from https://medicalxpress.com/news/2020-01-doctors-urged-post-antidepressant-sexual-dysfunction.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology